Get the Stockscreener App
309.89
1.58%
4.83
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Cencora Inc stock is traded at $309.89, with a volume of 833.38K.
It is up +1.58% in the last 24 hours and up +8.94% over the past month.
Cencora is one of three leading domestic pharmaceutical wholesalers. It sources and distributes branded, generic, and specialty pharmaceutical products to pharmacies (retail chains, independent, and mail order), hospital networks, and healthcare providers. It and McKesson and Cardinal Health hold over 90% share of the US pharmaceutical wholesale industry. Cencora also provides commercialization services for manufacturers of pharmaceuticals and medical devices, global specialty drug logistics (World Courier), and animal health product distribution (MWI Animal Health). Cencora expanded its international presence in 2021 by purchasing Alliance Healthcare, one of the leading drug wholesalers in Europe.
See More
Previous Close:
$305.06
Open:
$306.9
24h Volume:
833.38K
Relative Volume:
0.47
Market Cap:
$60.29B
Revenue:
$328.68B
Net Income/Loss:
$2.55B
P/E Ratio:
23.77
EPS:
13.0349
Net Cash Flow:
$1.56B
1W Performance:
+0.65%
1M Performance:
+8.94%
6M Performance:
-12.33%
1Y Performance:
+6.69%
1-Day Range:
$304.25
$310.30
1-Week Range:
$298.43
$310.30
52-Week Range:
$244.82
$377.54
Cencora Inc Stock (COR) Company Profile
Name
Cencora Inc
Sector
Industry
Phone
610-727-7000
Address
1 WEST FIRST AVENUE, CONSHOHOCKEN
Compare COR vs MCK, CAH, HSIC, AHG
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
COR
Cencora Inc
|
309.89 | 60.29B | 328.68B | 2.55B | 1.56B | 13.03 |
MCK
Mckesson Corp
|
840.90 | 98.45B | 403.43B | 5.10B | 5.41B | 38.47 |
CAH
Cardinal Health Inc
|
228.03 | 53.41B | 250.74B | 1.55B | 4.39B | 6.5398 |
HSIC
Henry Schein Inc
|
85.47 | 9.74B | 13.38B | 418.00M | 391.00M | 3.3112 |
AHG
Akso Health Group Adr
|
1.51 | 1.29B | 14.85M | -136.07M | 7.25M | -0.4726 |
Cencora Inc Stock (COR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-29-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-22-26 | Upgrade | Jefferies | Hold → Buy |
| Dec-09-25 | Initiated | Barclays | Overweight |
| Jun-03-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Dec-04-24 | Resumed | Mizuho | Outperform |
| Sep-18-24 | Downgrade | BofA Securities | Buy → Neutral |
| Feb-26-24 | Initiated | Leerink Partners | Outperform |
| Jan-03-24 | Initiated | Barclays | Overweight |
| Dec-14-23 | Initiated | Wells Fargo | Equal Weight |
| Mar-31-23 | Initiated | Citigroup | Buy |
| Jan-31-23 | Resumed | Evercore ISI | Outperform |
| Oct-11-22 | Upgrade | BofA Securities | Neutral → Buy |
| Aug-22-22 | Resumed | Morgan Stanley | Equal-Weight |
| Jul-11-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Jun-07-22 | Upgrade | Deutsche Bank | Hold → Buy |
| May-26-22 | Upgrade | Barclays | Equal Weight → Overweight |
| Apr-12-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-22 | Resumed | Credit Suisse | Outperform |
| Mar-12-21 | Resumed | Evercore ISI | In-line |
| Feb-04-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Feb-02-21 | Upgrade | Cowen | Market Perform → Outperform |
| Jan-06-21 | Upgrade | BofA Securities | Underperform → Neutral |
| Jan-06-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-10-20 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| Dec-03-20 | Initiated | Mizuho | Neutral |
| Aug-06-20 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Jul-15-20 | Initiated | Barclays | Underweight |
| Jun-15-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Apr-23-20 | Resumed | Credit Suisse | Outperform |
| Apr-16-20 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Apr-13-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Apr-01-20 | Upgrade | JP Morgan | Neutral → Overweight |
| Mar-17-20 | Upgrade | Citigroup | Neutral → Buy |
| Feb-11-20 | Downgrade | BofA/Merrill | Buy → Underperform |
| Feb-07-20 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Sep-12-19 | Initiated | Deutsche Bank | Hold |
| Jul-10-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Apr-11-19 | Initiated | Guggenheim | Buy |
| Apr-10-19 | Downgrade | BofA/Merrill | Buy → Underperform |
| Apr-10-19 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-11-19 | Downgrade | JP Morgan | Neutral → Underweight |
| Jan-17-19 | Initiated | UBS | Buy |
| Dec-10-18 | Downgrade | Jefferies | Buy → Hold |
| Oct-26-18 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Sep-20-18 | Initiated | Berenberg | Buy |
| Jul-17-18 | Resumed | Stifel | Hold |
| Apr-09-18 | Initiated | MoffettNathanson | Buy |
| Mar-12-18 | Upgrade | KeyBanc Capital Mkts | Sector Weight → Overweight |
| Mar-12-18 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Sep-25-17 | Initiated | JP Morgan | Neutral |
| Sep-22-17 | Initiated | William Blair | Outperform |
View All
Cencora Inc Stock (COR) Latest News
Cencora Inc (COR) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
COR|Cencora Inc|Price:309.890|Chg%:+4.765 - TradingKey
Cencora Inc. stock outperforms competitors on strong trading day - MarketWatch
Cencora (COR) Stock Could Be 39% Below Fair Value - simplywall.st
A4EQAC Bond Risk Profile - TradingView
Here's Why You Should Add Cencora Stock to Your Portfolio Now - TradingView
Zacks.com featured highlights include AIM ImmunoTech, Hasbro, Fox, Cencora and Intuitive Surgical - Yahoo Finance
Cencora stock holds steady as investors await fresh numbers - AD HOC NEWS
Cencora stock trades steady as specialty distribution scale and recent earnings shape investor view - AD HOC NEWS
COR stock consolidates after strong fiscal 2025 results and guidance update - Ad-hoc-news.de
Cencora: Specialty Infrastructure Is Rewriting The Distributor Model (NYSE:COR) - Seeking Alpha
Cencora earnings preview: What to expect - MSN
ABC5953643 Bond Risk Profile - TradingView
COR|Cencora Inc|Price:305.030|Chg%:+4.450 - TradingKey
Cencora stock trades steadily as pharmaceuticals distributor highlights rising revenue and earnings - Ad-hoc-news.de
Cencora, Inc. Stock 12‑Month Price Target Raised to $354.58, Implies 17% Upside - TradingView
ETFs Investing in Cencora, Inc. Stocks - TradingView
Cencora stock trades near record levels as earnings and guidance underpin healthcare distribution gr - Ad-hoc-news.de
Cencora Inc. stock underperforms Monday when compared to competitors - MarketWatch
Cencora stock holds firm as revenue and profit trends stay in focus - Ad-hoc-news.de
US3073EBC8 Bond Risk Profile - TradingView
Cencora stock trades near record levels as specialty distribution growth supports earnings - AD HOC NEWS
Steve Collis: Pharmaceutical Distribution Leader and Former Chairman, President, and CEO of Cencora - BBN Times
Cencora stock holds after fiscal 2026 growth update - ad-hoc-news.de
Cencora stock trades steadily as recent earnings highlight solid revenue growth - ad-hoc-news.de
XS3071246378 Bond Risk Profile - TradingView
XS3071246378 Bond Coupon Profile — Rate & Payments - TradingView
ABC6310083 Bond Coupon Profile — Rate & Payments - TradingView
XS3071246378 Bond Profile — Key Metrics - TradingView
Cencora stock trades steadily as specialty distribution growth supports earnings - Ad-hoc-news.de
Fund Update: 235,570 CENCORA (COR) shares added to FORT WASHINGTON INVESTMENT ADVISORS INC |OH| portfolio - Quiver Quantitative
Cencora Earnings Preview: What to Expect - inkl
A1ZW87 Bond Coupon Profile — Rate & Payments - TradingView
Lobbying Update: $60,000 of CENCORA INC. lobbying was just disclosed - Quiver Quantitative
ABC6310086 Bond Profile — Key Metrics - TradingView
Is Cencora Inc (COR) Overvalued After 3.9% Rally? GF Value Says - GuruFocus
Cencora stock reflects steady healthcare distribution role as investors track U.S. drug spending tre - ad-hoc-news.de
Cencora Inc. stock underperforms Wednesday when compared to competitors - MarketWatch
ABC5953320 Bond Risk Profile - TradingView
ABC4571978 Bond Coupon Profile — Rate & Payments - TradingView
How Cencora’s Revenue Miss Amid Growth Will Impact Cencora (COR) Investors - simplywall.st
ABC5953320 Bond Profile — Key Metrics - TradingView
ABC6310084 Bond Coupon Profile — Rate & Payments - TradingView
ABGB Bond Profile — Key Metrics - TradingView
ABC6310085 Bond Coupon Profile — Rate & Payments - TradingView
ABC4571978 Bond Profile — Key Metrics - TradingView
Cencora stock reflects steady growth as healthcare distribution evolves - Ad Hoc News
Cencora Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Cencora (COR) Following Soft Earnings Is The Stock Starting To Look Undervalued - simplywall.st
ABC4987224 Bond Risk Profile - TradingView
Cencora : World Courier Expands Cold Chain Capabilities | Cencora - marketscreener.com
Cencora Inc Stock (COR) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):